The Patent Finder

Modified FGF-21 Polypeptides and Their Uses

Ambrx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 7 of these applications claim priority to application 60/921,297, filed Mar 30, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,012,931Modified FGF-21 Polypeptides and Their Uses
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 8,383,365Methods of Making FGF-21 Mutants Comprising Non-Naturally Encoded Phenylalanine Derivatives
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 9,079,971Modified FGF-21 Polypeptides comprising non-naturally occurring amino acids.
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 9,517,273Methods of Treatment Using Modified FGF-21 Polypeptides Comprising Non-Naturally Occurring Amino Acids
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 10,377,805Modified FGF-21 Polypeptides Comprising Non-Naturally Encoding Amino Acids and Their Uses
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 10,961,291Modified FGF-21 Polypeptides and Their Uses
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 11,993,637Modified FGF-21 Polypeptides with Non-Naturally Encoded Amino Acids
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 9,975,936Nucleic Acids Encoding Modified FGF-21 Polypeptides Comprising Non-Naturally Occurring Amino Acids
Lapsed May 22, 2026 on the fee record
Ended May 22, 2026 · High confidence
Ambrx, Inc.Lapsed May 22, 2026 on the fee recordEnded May 22, 2026
High confidence
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Ambrx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited